Anzeige
Mehr »
Lynx Broker
Login
Sonntag, 20.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JS1K ISIN: IE00B4Q5ZN47 Ticker-Symbol: J7Z 
Tradegate
18.10.19
17:22 Uhr
107,00 Euro
-2,00
-1,83 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
JAZZ PHARMACEUTICALS PLC Chart 1 Jahr
5-Tage-Chart
JAZZ PHARMACEUTICALS PLC 5-Tage-Chart
RealtimeGeldBriefZeit
107,00
108,00
19.10.
107,00
108,00
18.10.
12.02.2019 | 22:07
(40 Leser)
(0 Bewertungen)

DUBLIN, Feb. 12, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2018 fourth quarter and full year financial results on Tuesday, February 26, 2019, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST/9:30 p.m. GMT to discuss fourth quarter and full year 2018 financial results and provide a business and financial update and guidance for 2019 financial results.

Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at http://www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for at least one week.

Audio webcast/conference call:
U.S. Dial-In Number: +1 855 353 7924
International Dial-In Number: +1 503 343 6056
Passcode: 7095707

A replay of the conference call will be available through March 5, 2019 and accessible through one of the following telephone numbers, using the passcode below:

Replay U.S. Dial-In Number: +1 855 859 2056
Replay International Dial-In Number: +1 404 537 3406
Passcode: 7095707

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, is dedicated to developing life-changing medicines for people with limited or no options. As a leader in sleep medicine and with a growing hematology/oncology portfolio, Jazz has a diverse portfolio of products and product candidates in development, and is focused on transforming biopharmaceutical discoveries into novel medicines. Jazz Pharmaceuticals markets Xyrem (sodium oxybate) oral solution, Erwinaze (asparaginase Erwinia chrysanthemi), Defitelio (defibrotide sodium) and Vyxeos (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinase, Defitelio (defibrotide) and Vyxeos 44 mg/100 mg powder for concentrate for solution for infusion in countries outside the U.S. For country-specific product information, please visit https://www.jazzpharma.com/medicines. For more information, please visit www.jazzpharmaceuticals.com and follow us on Twitter at @JazzPharma.

Jazz Pharmaceuticals Logo

Logo - https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_Logo.jpg


© 2019 PR Newswire